Brief: Fortress Biotech - Avenue Therapeutics Intends To Continue To Pursue Approval For IV Tramadol

Avenue Therapeutics

15/07/2021 11:45

July 15 (Reuters) - Avenue Therapeutics Inc  ATXI.O :
    * FORTRESS BIOTECH - AVENUE THERAPEUTICS INTENDS TO CONTINUE
TO
PURSUE APPROVAL FOR IV TRAMADOL & HAS TYPE A MEETING SCHEDULED
WITH FDA FOR LATE JULY
    * FORTRESS BIOTECH - AVENUE CURRENTLY EXPECTS TO SUBMIT A
FORMAL
DISPUTE RESOLUTION REQUEST WITH FDA FOLLOWING  MEETING
    * FORTRESS BIOTECH - AVENUE IS TARGETING A SUBMISSION OF
FDRR FOR
IV TRAMADOL IN THE THIRD QUARTER OF 2021

Source text for Eikon:  ID: 
Further company coverage:  ATXI.O 

 ((Reuters.Briefs@thomsonreuters.com;))